Baar (pta044/20.12.2019/18:15) - Baar, December 20, 2019
Based on the planning of Bogar AG for the year 2020, which was recently adopted by its Board of Directors, the Board of Directors of New Value AG has made a reassessment of the company. Based on the year-end closing of Bogar AG, which will be worse than expected, the Board of Directors of New Value AG judges the (previous) assumptions for the multi-year planning of Bogar AG as too ambitious, despite the expected positive development of Bogar AG in 2020. The revised valuation results in a value adjustment of Bogar AG of CHF 587 ` 474 (from CHF 0.35 per share to CHF 0.26 per share). This adjustment impairs the NAV (Net Asset Value) of New Value AG by CHF 0.18 per share.
The sale of Swiss Diagnostic AG, which was announced in the half-year report, could be closed in December at NAV-Value.
Sensimed SA could be sold to the japanese company Seed Co. Ltd. With this sale the bankruptcy of the company could be avoided. The sale of the already fully impaired shares (see press release of November 26, 2019) resulted in a marginal revenue for New Value AG.
About New Value
New Value AG, which is listed on the SIX Swiss Exchange, invests directly in private companies with strong growth potential in Switzerland and neighbouring countries. New Value AG provides growth capital to promote innovative business models and supports the companies to market success. The companies included in the portfolio are mainly related to the cleantech and healthcare sectors.
Stock exchange listings: SIX Swiss Exchange (www.six-swiss-exchange.com)
Ticker symbols NEWN (CH)
Security number 1 081 986
Contact New Value AG, Zugerstrasse 8a, CH-6340 Baar, Switzerland
Dr. Bernd Pfister
Phone +41 43 344 38 38
downloads www.newvalue.ch Email: email@example.com